Objective-Calcific aortic valve (AoV) disease is a significant clinical problem for which the regulatory mechanisms are poorly understood. Enhanced cell-cell adhesion is a common mechanism of cellular aggregation, but its role in calcific lesion formation is not known. Cadherin-11 (Cad-11) has been associated with lesion formation in vitro, but its function during adult valve homeostasis and pathogenesis is not known. This study aims to elucidate the specific functions of Cad-11 and its downstream targets, RhoA and Sox9, in extracellular matrix remodeling and AoV calcification. Approach and Results-We conditionally overexpressed Cad-11 in murine heart valves using a novel double-transgenic Nfatc1 Cre ;R26-Cad11 TglTg mouse model. These mice developed hemodynamically significant aortic stenosis with prominent calcific lesions in the AoV leaflets. Cad-11 overexpression upregulated downstream targets, RhoA and Sox9, in the valve interstitial cells, causing calcification and extensive pathogenic extracellular matrix remodeling. AoV interstitial cells overexpressing Cad-11 in an osteogenic environment in vitro rapidly form calcific nodules analogous to in vivo lesions. Molecular analyses revealed upregulation of osteoblastic and myofibroblastic markers. Treatment with a Rho-associated protein kinase inhibitor attenuated nodule formation, further supporting that Cad-11-driven calcification acts through the small GTPase RhoA/Rho-associated protein kinase signaling pathway.
C alcific aortic valve (AoV) disease (CAVD) is an increasingly prevalent and extremely debilitating disease that currently affects >25% of Americans over the age of 65 years. 1, 2 Individuals experiencing even earlier onset of CAVD have increased risk for heart attacks, atherosclerosis, stroke, and heart failure. 3 The development of calcific lesions on the AoV in CAVD causes thickening and stiffening of the thin, fibrous leaflets because of disruptions in the extracellular matrix (ECM) and leads to stenosis and regurgitation. CAVD can only be diagnosed in later stages through echocardiography as no clinically useful biomarkers have been identified. 4, 5 Statins targeted at lowering serum cholesterol have been disappointing in clinical trials, 6 further highlighting the lack of available biological diagnostic and therapeutic agents available for treatment. The only existing therapy for valve disease is biological or mechanical prosthetic replacement because there are no medications to slow the progression of the disease. 7 Recent investigations into the mechanisms responsible for AoV disease have suggested that a complex interplay of molecular signaling and cell phenotypes influenced by the microenvironment and hemodynamics contribute to valve degeneration. [8] [9] [10] Heart valves consist of an organized, trilaminar ECM to ensure proper biomechanical function, and disruptions in ECM organization can cause serious valve impairment. 8 Inflammatory cytokines, anisotropic strain, reduced nitric oxide signaling, and oxidative stress have all been shown to contribute to ECM remodeling and calcification. [11] [12] [13] [14] [15] Calcific lesions exhibit characteristics of both dystrophic (apoptotic cell aggregates) and osteogenic (osteoblast, bone-like) calcification. 16 In addition, reactivation of certain developmental pathways may promote valve remodeling, preceding osteoblastic differentiation in valve interstitial cells (VICs). 10 promotes differentiation of mesenchymal cells to osteo-and chondro-lingeages. 17 Dysregulated Cad-11 expression contributes to inflammation, cartilage degradation, and metastasis in diseases, such as pulmonary fibrosis, rheumatoid arthritis, and multiple cancer types. [18] [19] [20] [21] [22] [23] Previous reports have demonstrated increased Cad-11 expression in aortic VICs in adult ApoE −/− mice and calcified human valves. 24, 25 Furthermore, Cad-11 depletion disrupts embryonic valve formation and remodeling through inactivation of GTP-RhoA and Sox9, but prevents calcification in adult mice. 26 These results suggest a potential link between cell-cell and cell-matrix interactions, which may influence matrix production and calcification.
Cadherin-binding-mediated signaling functions upstream of Rho family GTPases (CDC42, RhoA, and Rac1), which regulate cell protrusion, contractility, and stress fibers leading to myofibroblast activation. 27, 28 RhoA/Rho-associated protein kinase (ROCK) expression is associated with calcification in VICs and vascular smooth muscle cells, and inhibition of ROCK attenuates calcification. [29] [30] [31] [32] ROCK additionally activates the transcription factor and ECM regulator, Sox9, via serine phosphorylation to promote cartilage matrix production, 33 and recent reports highlight an additional role for Sox9 in valve calcification. [34] [35] [36] These results suggest a multifaceted mechanism that links inter and intracellular signaling with the extracellular microenvironment to promote valve pathogenesis because increased cell-cell contacts, myofibroblast contractility, and collagen/proteoglycan deposition are all common features of CAVD. 8 We, therefore, hypothesized that Cad-11 mediates the mechanosensitivity of VICs via RhoA/ROCK to ensure proper homeostatic ECM maintenance through Sox9.
In this study, we identified a mechanism by which Cad-11 contributes to adult valve calcification and ECM remodeling in vitro and in vivo via RhoA/Sox9. We report that mice-overexpressing Cad-11 in the valves display extensive ECM remodeling and develop calcific lesions on the AoVs with increases in myofibroblastic and osteoblastic markers at 10 months of age. These valves are functionally deficient when evaluated with echocardiography. This calcific phenotype was recapitulated with Cad-11 overexpression (Cad-11 OX) in porcine aortic valve interstitial cells (PAVICs), but it is attenuated with ROCK inhibition in vitro. These expression patterns were similarly found to be present in calcified human valves. Collectively, these results demonstrate that dysregulation of Cad-11 contributes to valve pathogenesis and identify Cad-11/RhoA/ROCK/ Sox9 signaling as a potential pathway for therapeutic targets in treating and slowing the progression of AoV disease.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Cad-11 OX Induces ECM Remodeling but Is Not Embryonic Lethal
To study the effects of Cad-11 in AoV calcification, we created a novel double-transgenic mouse model that conditionally overexpresses Cad-11 in the heart valves. Cad-11 transgenic floxed mice (Rosa26-LSL-Cad11 Tgl+ ) were created using targeted embryonic stem cell microinjection into C57BL/6 mice. Full-length Cad-11 cDNA preceded by a floxed stop region was inserted into the ROSA26 locus via bacterial artificial chromosome transgenesis. These mice were crossed with Nfatc1 Cre mice to achieve valve-specific conditional overexpression of Cad-11 ( Figure 1A ) and have been previously described in which the Cre reporter gene is expressed in endocardial cells and in the cushion mesenchyme derived from the endocardium, but it is not expressed in the epicardium or myocardium. 37, 38 Presence of transgenes were confirmed using polymerase chain reaction ( Figure 1B) , and homozygous floxed mice express approximately a 5-fold increase of Cad-11 compared with wild-type (WT) mice ( Figure SIA in the online-only Data Supplement). We crossed Nfatc1 Cre ;R26-Cad11 Tgl+ mice, genotyped litters at birth, and found that homozygous (Nfatc1 Cre ;R26-Cad11 TglTg ), heterozygous (Nfatc1 Cre ;R26-Cad11 Tgl+ ), and WT (Nfatc1 Cre ;R26-Cad11 +l+ ) mice were present at expected Mendelian ratios (Table SI in the online-only Data Supplement, P=0.18). These mice had normal litter sizes that averaged 10.7 mice per litter (n=6) and had no visible physical defects. In addition, Cad-11 OX mice display no significant differences in AoV thickness or cross-sectional area at 1 month ( Figure SIIA in the onlineonly Data Supplement). These data show that valve-specific Cad-11 overexpression does not affect valve development and that Cad-11 OX offspring are viable.
Histological analysis reveals that AoVs of 10 months old, valve-specific Cad-11 OX Nfatc1 Cre ;R26-Cad11 TglTg mice are significantly thickened (>70%) and have greater crosssectional area (>46%) compared with WT Nfatc1 Cre ;R26-Cad11 +/+ control mice ( Figure 1C through 1E). Given these structural abnormalities in the Cad-11 OX mice, we suspected defects in the extracellular architecture and makeup of the AoVs. We profiled the 3 main ECM proteins that compose the AoV: glycosaminoglycans, collagen, and elastin. Cad-11 OX AoVs express significantly higher glycosaminoglycans and collagen compared with controls ( Figure 1F Together, these results demonstrate that Cad-11 affects the ECM and morphology of mature AoVs postnatally.
Cad-11 OX Results in Calcification and Aortic Stenosis
Increased glycosaminoglycans and collagen are hallmarks of CAVD, 8 which led us to stain for the calcification in the AoVs. Cad-11 OX valves exhibit 8.3% mineralization ( the online-only Data Supplement), and no differences were found in aortic root diameters ( Figure SIF in the online-only Data Supplement), supporting AoV leaflet-driven calcification as the cause of these CAVD-like symptoms. These results strongly suggest that Cad-11 plays a role in the progression of AoV calcification that promotes valvular and ventricular degeneration.
Cad-11 OX Upregulates GTP-RhoA and Sox9
We examined the expression of RhoA (GTP bound) and Sox9 because of their previously implicated roles in cardiovascular calcification and glycosaminoglycan/collagen production, respectively. Immunofluorescent staining reveals upregulation of both RhoA and Sox9 in Cad-11 OX AoVs beginning at 1 month ( Figure SIIC and SIID in the online-only Data Supplement). At 10 months, GTP-RhoA expression is 4.3× higher in Cad-11 OX leaflets compared with WT controls ( Figure 3C ). Interestingly, RhoA expression is more highly expressed in the valve endothelium ( Figure 3A , white arrows) compared with the interstitium in WT mice, whereas RhoA is robustly expressed throughout the entire valve in Cad-11 OX mice ( Figure 3B , white arrowheads). Cad-11 OX mice have a 2.25-fold increase in overall Sox9 expression ( Figure  3D through 3G). These results collectively suggest that GTP-RhoA and Sox9 are downstream targets of Cad-11 and promote calcification and ECM remodeling.
Cad-11 OX Increases Cell Adhesion, Migration, Compaction, and Stress Fiber Bundles
We first investigated the effects of Cad-11 on GTP-RhoA and for Cad-11 in calcification through cell-matrix compaction and cell-cell adhesivity. We examined the effects of Cad-11 OX on GTP-RhoA/Sox9 expression and cell morphology to determine mechanisms that affect compaction and migration. We found that overexpression of Cad-11 increases GTP-RhoA and Sox9 expression in PAVICs after 2 days ( Figure 4A through 4D ). Sox9 is highly colocalized to the nuclei of Cad-11-transfected PAVICs, but it is attenuated with the ROCK inhibitor (Y27632), showing that Cad-11 induces Sox9 nuclear localization in a ROCK-dependent manner (white arrowheads, Figure 4E and 4F). Control cells seeded at a low density and stained for F-actin exhibit a normal fibroblast shape with multiple lamellipodia, few filopodia, and some stress fiber bundles ( Figure 5A and 5D ). In contrast, Cad-11 OX PAVICs display multiple filopodia and parallel stress fibers ( Figure 5B and 5E ). Addition of Y27632 to Cad-11-transfected cells did not affect filopodia protrusions (white arrowheads), as shown by the ratio of filopodia to lamellipodia (Figure 5C , 5F, and 5G). High-density seeding reveals Cad-11-transfected cells to have an almost 3-fold increase in stress fiber bundle-positive cells compared with control cells (white arrows), which is mitigated with Y27632 ( Figure 5H through 5K ).
Cad-11-Induced Calcification Is RhoA/ROCK Dependent
We further examined the role of Cad-11 in calcification by placing PAVICs in osteogenic growth media (OGM). After 10 days, cells in regular media do not calcify, whereas cells in OGM show numerous calcific nodules, which are decreased with Y27632 ( Figure SVIIIA through SVIIIC in the online-only Data Supplement). Brightfield imaging shows aggregation of cells, and live/dead staining of the calcific nodules reveals that these nodules have a partially apoptotic core ( Figure SVIIID and SVIIIE in the online-only Data Supplement). Compared to cells in regular growth media, PAVICs placed in OGM display a 14.8fold increase in Cad-11 mRNA, along with increases in α-SMA, RhoA, Sox9, Runx2, and osteocalcin. Addition of Y27632 to OGM decreases Cad-11 and RhoA expression, and restores Sox9, α-SMA, Runx2, and osteocalcin to control or near-control levels ( Figure SVIIIF in the online-only Data Supplement).
Cad-11-transfected PAVICs were next analyzed for calcific nodule formation. At day 10, Cad-11 OX PAVICs in OGM average 92 nodules and greater Alizarin Red activity compared with control cells, which average 47 nodules ( Figure  6A through 6E), and they have significantly upregulated α-SMA, RhoA, Sox9, Runx2, and osteocalcin compared with control cells as shown by quantitative reverse transcription polymerase chain reaction ( Figure 6F ). Addition of Y27632 attenuates excessive calcification and gene expression even with Cad-11 OX ( Figure 6C through 6F) . Cad-11 OX alone is sufficient to induce calcific nodule formation through dystrophic and osteogenic mechanisms, but these nodules are much smaller and reduced by Y27632 ( Figure SIXA through SIXE in the online-only Data Supplement). These results demonstrate that the Cad-11/RhoA/ROCK signaling pathway actively contributes to nodule formation through dystrophic and osteogenic programs and may be a potential target in therapeutic treatment to reduce calcification. Figure 7F through 7H) , but both the regions have higher expression compared with control AoVs (Figure 7A through 7D) . β1-Integrin, α-SMA, and Runx2 are also elevated in CHAV compared with controls with calcified regions having higher expression than noncalcified regions ( Figure SXIA through SXIJ in the online-only Data Supplement). Together, this suggests that the Cad-11/ RhoA/Sox9 pathway is a clinically relevant mechanism that is associated with increased cell-matrix adhesions and promotes both dystrophic and osteogenic calcification.
Discussion
Homeostatic maintenance of the cellular architecture in the heart valve must be preserved in order for long-term, efficient cardiac performance. Valve thickening and stiffening caused by calcification compromise this finely tuned, unidirectional diode-like function, ultimately leading to regurgitation and stenosis. CAVD has no clinically useful biomarkers for diagnosis or medications to slow the progression of the disease, so identification of signaling pathways that mediate valve homeostasis and initiate progression of disease is critical to the development of potential diagnostic and therapeutic targets. 5, 7, 10 Excessive cadherin-binding-mediated signaling increases the small GTPase RhoA, having profound effects on cell behavior, phenotype, and gene expression. In this study, we present evidence that Cad-11 actively participates in calcification and matrix remodeling in the AoV upstream of RhoA and Sox9, directing VICs toward myofibroblast and osteoblast phenotypes. Previous studies have highlighted the role of Cad-11 in maintenance of a fibroblastic phenotype with increased levels leading to inflammation and tissue disorganization. 18, 21, [39] [40] [41] CHAVs express a 50-fold increase in Cad-11 mRNA, and Cad-11-positive cells are highly colocalized with myofibroblast and osteoblast markers in diseased human and mouse valves. 24, 25 Interestingly, adult Cad-11 −/− mice have thickened, hemodynamically stenotic valves and decreased GTP-RhoA expression, but lack calcification suggesting that Cad-11 insufficiency is protective of calcification potentially through reduced myofibroblastic activation. This persistent valve thickening is a consequence of defective cellular distribution in valve cushions and subsequent valve compaction and elongation. 26 Cad-11 OX valves were also thickened, but this thickening occurs because of proliferation preceding increased ECM proteins from excessive remodeling and calcification via active dystrophic and osteogenic mechanisms. Tanaka et al 42 found ApoE −/− mice to develop calcified and stenotic AoVs in an age-dependent manner characterized by elevated transaortic velocity and regurgitation. Cad-11 OX mice also develop aortic stenosis and calcification at 10 months of age as indicated by an average ejection velocity of >1600 mm/s, regurgitation, presence of osteoblastic markers, and positive Von Kossa and Alizarin Red staining, resulting in remodeling of the left ventricle. These findings elevate the role of cell-cell adhesive signaling in maintaining the homeostatic integrity of the valve architecture necessary for proper function in adulthood and provide opportunities for modulation of adhesive signaling in disease treatment.
Cad-11 promotes inflammation, collective migration, invasion, and proliferation in many cell types, including mesenchymal, vascular smooth muscle, cancer, fibroblasts, and neural crest cells. [20] [21] [22] [23] [43] [44] [45] [46] [47] Furthermore, Cad-11 promotes osteogenic differentiation in the context of bone growth and development, and it additionally plays a role in myofibroblastic activation in dermal and pulmonary fibrosis. [48] [49] [50] Cad-11 provides the necessary cell-cell tension for aggregation and calcification of valvular myofibroblasts, 25 likely mediated by RhoA and favoring a procalcific environment as we show here. Cad-11 increases stress fibers, compaction, and collective migration. Stress fiber bundles may indicate cell tension, which is conducive toward calcific nodule formation and demonstrate the role of Cad-11 in mechanosensation. Notably, small GTPases interact with pathogenic pathways such as transforming growth factor-β, 51 suggesting that an interlocking network of mechanisms is collectively responsible for CAVD. ROCK inhibition mitigates Cad-11-induced mechanosensitivity and calcification as shown by decreased formation of stress fibers, calcific nodules, and osteoblastic genes. Together, these results indicate that Cad-11 increases cell sensitivity to mechanical tension through RhoA signaling and promotes interstitial differentiation into myofibroblasts and osteoblasts.
CHAV and Cad-11 OX mice have increased Sox9 expression in the AoVs, and CHAV show higher expression in calcified regions compared with noncalcified regions. Cad-11 has been shown to direct mesenchymal cells to osteo-and chondral-lineages, 17 whereas Sox9 promotes chondrogenesis and prevents osteogenesis by inhibiting Runx2. 52 Both calcification and chondrogenesis are present in CAVD, 16, 53 and Sox9 mRNA and protein expression are elevated in CHAV leaflets, although differences between calcified and noncalcified regions were not examined. 36, 54 Previous studies have shown that although reduced Sox9 promotes valve calcification, Sox9 overexpression induces chondrogenesis via β-catenin signaling. 34, 35, 55 Together, these results suggest conflicting roles for Sox9 in CAVD. Chondrogenesis and osteogenesis may not be mutually exclusive as mesenchymal stem cells seeded on a collagen/fibronectin/Cad-11-coated surface coexpress Sox9 and Runx2. 56 We postulate that initial Cad-11/RhoA-induced myofibroblasts increase ECM production via Sox9 because previous studies have identified serine phosphorylation of Sox9 by ROCK as a mechanism of nuclear translocation. 33 RhoA activity increases with matrix stiffness, and high RhoA activity directs mesenchymal progenitors to osteogenic lineages. [57] [58] [59] Increased matrix stiffness and adhesivity, as indicated by increased β1-integrin, may upregulate RhoA in a positive feedback manner until sufficient to induce osteogenic differentiation. Furthermore, increased ECM stiffness promotes both chondrogenesis and calcification, especially in VICs. 8, [60] [61] [62] [63] The temporal and spatial expression pattern of the Cad-11/RhoA/ Sox9 pathway, mechanisms of Sox9 nuclear translocation, and the dependency of this pathway on matrix stiffness in CAVD remain elusive but certainly warrant further investigation as current evidence places an emphasis on cell-cell and cell-matrix adhesions in determining valve pathobiology by demonstrating the role of tissue stiffness and cellular microenvironment in controlling cell fate. Cholesterol-lowering drugs as a means of treating CAVD have proven to be ineffective in previous clinical trials. 6 Treatments that target pathways mediating cell-adhesion interactions may show more promise by mitigating cell-cell tension and maintaining a fibroblastic phenotype. Inhibition of RhoA/ROCK has been shown to mitigate calcific nodule formation in previous studies, and known functions of the small GTPases suggests that this process involves actin dynamics and cytoskeletal reorganization. 29 Favorable cell phenotypes also prevent excess secretion of ECM proteins, contributing to the maintenance of healthy cell-matrix interactions. Our findings show that inhibition of RhoA/ROCK signaling relieves cell tension and is sufficient to prevent excessive calcification, mitigate Sox9 expression, and reduce mRNA levels of myofibroblastic and osteogenic markers, supporting this pathway as a target for prevention of cadherin small GTPase-mediated calcification along with its extracellular consequences. ROCK directly phosphorylates Sox9, contributing to cartilage matrix production in response to transforming growth factor-β signaling and supporting our findings that ROCK inhibition decreases Sox9 expression and nuclear localization downstream of RhoA. 33 Both guanine dissociation inhibitors and GTPase-activating proteins facilitate the conversion of GTP-RhoA to its inactive GDP-bound form and may function as better regulators of RhoA signaling in the clinical treatment. 64 Furthermore, certain domains of Cad-11 play specific functions in mediating cell polarity and cell-cell interactions, and targeting these specific domains may prove to be most effective. 65, 66 Future work investigating the benefits of these inhibitors for prevention or treatment of CAVD may help clinicians arrive at a therapeutic solution to the debilitating disease. Altogether, we establish the pathological nature of Cad-11 OX in AoV calcification, preceded by myofibroblastic and osteoblastic differentiation, and its relevance in human valvulopathy. We identify RhoA and Sox9 as downstream targets of Cad-11 whose upregulation causes excessive mechanical activation and ECM remodeling, resulting in morphogenic consequences that seriously impair valve function. Finally, we identify ROCK inhibition as a potential means of molecular, therapeutic intervention to halt disease progression and restore healthy valve phenotypes that should be clinically pursued. These results demonstrate the importance of cell-cell interactions in maintaining valve architecture across the lifespan because abnormal expression in both development and adulthood have pathological consequences. 
